Bio-Techne Corporation recently reported past second-quarter and six-month results to December 31, 2025, with sales essentially flat year-on-year at about US$295.88 million for the quarter and US$582.

Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market open. Here’s ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...

Shares of Bio-Techne Corp. TECH slid 4.09% to $65.86 Thursday, on what proved to be an all-around grim trading session for ...

RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...